5 recruiting, 4 completed, 4 unknown, 1 terminated. 7 Phase 2, 3 Phase 4, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 2, Recruiting 2, Unknown 2, Terminated 1 |
| Phase 4 | 3 | Completed 2, Unknown 1 |
| Phase 1 | 1 | Unknown 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Kaposiform Hemangioendothelioma: new trials by email Literature Review of Kaposiform Hemangioendothelioma trials Research Report on Kaposiform Hemangioendothelioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Low- vs High-Dose Sirolimus With Prednisolone for KHE and KMP Sirolimus (RAPAMUNE) - Kaposiform Hemangioendothelioma (KHE), Kasabach Merritt Phenomenon | Phase 2 / Phase 3 | Recruiting | Yi Ji | 76 | 2026-06-16 | 2026-06-18 |
| Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma Sirolimus - Kaposiform Hemangioendothelioma | Phase 2 | Recruiting | West China Hospital | 120 | 2025-09-13 | 2026-09-25 |
| Different Doses of Sirolimus for the Maintenance Treatment of Kaposiform Hemangioendothelioma Sirolimus - Hemangioendothelioma | Phase 2 | Unknown | West China Hospital | 30 | 2022-04-05 | 2024-01-24 |
| Percutaneous Administration of Sirolimus in the Treatment of Superficial Complicated Vascular Anomalies Percutaneous sirolimus, Oral sirolimus - Kaposiform Hemangioendothelioma, Tufted Angioma | Phase 4 | Unknown | Children's Hospital of Fudan University | 75 | 2021-10-22 | 2024-03-15 |
| The Effect of Sirolimus on Immunizations During the Treatment of Kaposiform Hemangioendothelioma Kaposiform Hemangioendothelioma | Recruiting | Children's Hospital of Fudan University | 174 | 2021-03-01 | 2025-06-27 | |
| Efficacy and Safety of Different Concentrations of Sirolimus in the Treatment of Kaposiform Hemangioendothelioma. Sirolimus - Kaposiform Hemangioendothelioma | Phase 2 | Completed | West China Hospital | 79 | 2021-02-17 | 2024-05-07 |
| Guided Discontinuation Versus Maintenance Treatment of Sirolimus in Pediatric Patients With Kaposiform Hemangioendothelioma Sirolimus - Kaposiform Hemangioendothelioma, Kasabach-Merritt Syndrome | Phase 4 | Completed | Children's Hospital of Fudan University | 30 | 2020-07-01 | 2023-09-26 |
| SCMC Trial on KHE With KMP (V.2020) prednison and Sirolimus, prednison - Kaposiform Hemangioendothelioma (KHE) With Kasabach-Merritt Phenomenon (KMP) | Phase 1 | Unknown | Shanghai Children's Medical Center | 20 | 2020-07-01 | 2020-06-09 |
| Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma Tacrolimus ointment - Tacrolimus, Kaposiform Hemangioendothelioma, Tufted Angioma | Phase 2 | Unknown | West China Hospital | 50 | 2019-09-01 | 2024-05-07 |
| Safety and Efficacy of Low-dose Sirolimus to Kaposiform Hemangioendothelioma Sirolimus(0.8mg/m2), Sirolimus(0.7mg/m2) - Hemangioma, Kaposiform Hemangioendothelioma | Phase 4 | Completed | Children's Hospital of Fudan University | 92 | 2019-05-01 | 2023-01-30 |
| A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors Vincristine, Sirolimus - Kaposiform Hemangioendothelioma (KHE), Kasabach-Merritt Syndrome | Phase 2 | Terminated | Boston Children's Hospital | 4 | 2017-06-14 | 2023-09-21 |
| Sirolimus Versus Sirolimus Plus Prednisolone for Kaposiform Hemangioendothelioma Sirolimus, Prednisolone - Kaposiform Hemangioendothelioma, Kasabach Merritt Phenomenon | Phase 2 | Completed | West China Hospital | 30 | 2017-06-01 | 2022-04-21 |
| Identification of Biomarkers for Patients with Vascular Anomalies Vascular Anomaly, Generalized Lymphatic Anomaly | Recruiting | Children's Hospital Medical Center, Cincinnati | 1000 | 2015-04-01 | 2024-11-06 | |
| Lymphatic Anomalies Registry for the Assessment of Outcome Data Lymphatic Malformation, Generalized Lymphatic Anomaly (GLA) | Recruiting | Boston Children's Hospital | 1000 | 2013-06-01 | 2026-09-10 |
Kasabach-Merritt Syndrome (5) · Tufted angioma (4) · Vascular Malformations (3) · Congenital Lipomatous Overgrowth, Vascular Malformations, and Epidermal Nevi (2) · Hemangioendothelioma (2) · Klippel-Trenaunay-Weber Syndrome (2) · Osteolysis, Essential (2) · Blue rubber bleb nevus syndrome (1) · Hemangioma (1) · Lymphatic Abnormalities (1)
Hemic and Lymphatic Diseases (6) · Neoplasms (6) · Neoplasms by Histologic Type (6) · Neoplasms, Vascular Tissue (6) · Blood Platelet Disorders (5) · Cytopenia (5) · Hemangioma (5) · Hematologic Diseases (5) · Thrombocytopenia (5) · Cardiovascular Abnormalities (3) · Cardiovascular Diseases (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Angiomatosis (2) · Bone Diseases (2)
Sirolimus (10) · Prednisolone (1) · Prednisone (1) · Vincristine (1)
West China Hospital (5) · Children's Hospital of Fudan University (4) · Boston Children's Hospital (2) · Children's Hospital Medical Center, Cincinnati (1) · Shanghai Children's Medical Center (1) · Yi Ji (1)
China (11) · United States (3)
Yi Ji, MD, PhD (3) · Kai Li, MD, PhD (2) · Yi Ji (2) · Denise Adams, MD (1) · Jiangyuan Zhou, MD (1) · Kai Li, PhD (1) · Marilyn Liang, M.D. (1) · Timothy LeCras, PhD (1) · Yi Ji, PhD (1)
PMID 35030255, PMID 28486787, PMID 31489702, PMID 32014025, PMID 22871490, PMID 33580918, PMID 34273457, PMID 39831682, PMID 40107509, PMID 23796341, PMID 24252784, PMID 28782106, PMID 29388191, PMID 30396415, PMID 31030813, PMID 34082006, PMID 3691614, PMID 36916140, PMID 3936944, PMID 41831614, PMID 42657977